UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA.
Vedic Lifesciences, 203 Morya Landmark1, New Link Road, Andheri W, Mumbai 400053, India.
Nutrients. 2020 Jan 30;12(2):363. doi: 10.3390/nu12020363.
This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, DDS-1 (1 × 10 CFU/day) or subsp. UABla-12 (1 × 10 CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: -2.59 ± 2.07, p = 0.001; UABla-12: -1.56 ± 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p < 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (-133.4 ± 95.19, p < 0.001) and B. lactis UABla-12 (-104.5 ± 96.08, p < 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.
这项随机、双盲、安慰剂对照、多中心研究调查了两种益生菌菌株对腹痛严重程度和肠易激综合征（IBS）症状的临床疗效。330 名年龄在 18 至 70 岁之间的 IBS 患者（根据罗马 IV 标准）被随机分配（1:1:1）接受安慰剂、DDS-1（每天 1×10 CFU）或 subsp。UABla-12（每天 1×10 CFU），共 6 周。主要结局是腹痛严重程度-数字评定量表（APS-NRS）的变化。在干预期间，与安慰剂组相比，DDS-1 和 UABla-12 益生菌组的 APS-NRS 在绝对值（DDS-1：-2.59 ± 2.07，p = 0.001；UABla-12：-1.56 ± 1.83，p = 0.001）和显著缓解应答者比例（DDS-1：52.3%，p < 0.001；UABla-12：28.2%，p = 0.031）均有显著改善。与安慰剂相比，L. acidophilus DDS-1（-133.4 ± 95.19，p < 0.001）和 B. lactis UABla-12（-104.5 ± 96.08，p < 0.001）益生菌组的 IBS 症状严重程度评分（IBS-SSS）也有显著改善，包括与腹痛、腹胀、肠道习惯和生活质量相关的亚评分。此外，在这两个益生菌组中，粪便稠度随着时间的推移和与安慰剂相比均有显著改善。总之，L. acidophilus DDS-1 和 B. lactis UABla-12 改善了 IBS 成人的腹痛和症状严重程度评分，并相应地使肠道习惯正常化。
